Try our Advanced Search for more refined results
Federal Trade Commission et al v. Vyera Pharmaceuticals, LLC et al
Case Number:
1:20-cv-00706
Court:
Nature of Suit:
Judge:
Firms
- Armstrong Teasdale
- Bennett Bricklin
- Calcagni & Kanefsky
- Chiesa Shahinian
- Crowell & Moring
- Dechert LLP
- DLA Piper
- Dorsey & Whitney
- Duane Morris
- Goodwin Procter
- Kang Haggerty
- Kasowitz Benson
- Kishner Miller
- Morgan Lewis
- Morgan Melhuish
- Obermayer Rebmann
- Phillips Nizer
- Sheppard Mullin
- Whiteford Taylor
- Wilson Sonsini
Companies
- Cardinal Health Inc.
- Cencora Inc.
- Cerovene Inc.
- Medisca Pharmaceutique Inc.
- Teva Pharmaceutical Industries Ltd.
- Vyera Pharmaceuticals LLC
Government Agencies
Sectors & Industries:
-
April 28, 2021
Rollback Of Restitution Power Leaves FTC Cases In Limbo
The U.S. Supreme Court's ruling last week in AMG Capital v. FTC all but stripped the Federal Trade Commission of its ability to recoup money from lawbreakers in federal court and the agency's pending cases are sure to feel the impact.
-
March 30, 2021
No Jury, No Forfeiture For 'Pharma Bro' Shkreli In FTC Case
Martin Shkreli dropped demands for a jury trial on Tuesday and, in exchange, seven U.S. states agreed not to seek civil penalties or forfeitures in a Federal Trade Commission-led lawsuit, which claims the former biopharma executive and his company Vyera blocked rivals from developing generic versions of the anti-parasite drug Daraprim.
-
January 25, 2021
'Pharma Bro' Shkreli Can't Have FTC Prison Call Transcripts
The Federal Trade Commission does not have to provide Martin Shkreli with transcripts of phone calls he made from prison, a New York federal judge ruled Monday, saying the agency already shared the audio recordings with the infamous ex-pharmaceutical executive.
-
January 08, 2021
Shkreli Can't Pause Suit Pending Prison Release, Judge Says
A New York federal court on Friday denied "Pharma Bro" Martin Shkreli's request to stay discovery in the Federal Trade Commission and states' lawsuit against him until he is released from prison in 2023, stating that the 37-year-old had not shown "good cause" to stay the proceedings.
-
December 22, 2020
Shkreli Can't Delay January FTC Deposition, NY Judge Says
Martin Shkreli can't push back his deposition set for next month in the Federal Trade Commission's monopolization case against him and his company, a New York federal judge ruled Tuesday, rejecting the incarcerated "pharma bro's" request to delay it until late February.
-
November 30, 2020
Judge Won't Quickly Pause Discovery In Shkreli's FTC Case
A New York federal judge said Monday she won't immediately grant the request of incarcerated "pharma bro" Martin Shkreli to pause discovery in a monopolization case the Federal Trade Commission brought against him earlier this year.
-
November 12, 2020
Shkreli's Objections To FTC Prison Comms Access Tossed
A New York federal judge overruled objections from incarcerated "pharma bro" Martin Shkreli regarding the Federal Trade Commission's access to his prison telephone communications, in the FTC's legal challenge against Shkreli on charges of monopolizing sales of the anti-parasitic drug Daraprim.
-
October 29, 2020
FTC Says Shkreli Can't Relitigate Authority Challenge
The Federal Trade Commission and several state attorneys general continue to argue that incarcerated "Pharma Bro" Martin Shkreli should be blocked from arguing that they lack the authority to sue him on charges of monopolizing sales of the anti-parasitic drug Daraprim.
-
October 22, 2020
Shkreli Says FTC Can't Nix Challenge To Authority
Martin Shkreli urged a New York federal judge Wednesday not to let the Federal Trade Commission and several state attorneys general block him from arguing they lack the authority to sue the incarcerated "Pharma Bro" for monopolizing sales of the anti-parasitic drug Daraprim.
-
August 20, 2020
Shkreli's Prison Comms Get Partial Protection From FTC
A New York federal judge on Thursday ordered the Federal Trade Commission to "make reasonable efforts" not to look at Martin Shkreli jailhouse communications with his attorneys but otherwise permitted a look at other conversations the incarcerated "pharma bro" may have had about monopolizing sales of the antiparasitic drug Daraprim.